10-K: Capricor Therapeutics: Deramiocel BLA Resubmission & HOPE-3 Data

Capricor Therapeutics' Deramiocel for Duchenne muscular dystrophy receives a new FDA PDUFA target action date of August 22, 2026, following positive Phase 3 HOPE-3 trial results and a resubmission addressing a prior Complete Response Letter.

Summary

• Capricor Therapeutics is a biotechnology company focused on the development and potential commercialization of cell and exosome-based therapeutics for Duchenne muscular dystrophy (DMD) and other diseases with significant unmet medical need.
• The lead product candidate, Deramiocel, a cell therapy for DMD, is currently under U.S. FDA review with a Prescription Drug User Fee Act (PDUFA) target action date of August 22, 2026, for potential approval.
• The FDA issued a Complete Response Letter (CRL) in July 2025, requesting additional clinical data, which was subsequently submitted and accepted as a Class 2 resubmission.
• Positive topline results from the Phase 3 HOPE-3 trial were announced in December 2025, showing statistical significance in the primary endpoint (PUL v2.0 Total Score, 54% slowing of progression, p=0.029) and key secondary cardiac endpoint (Left Ventricular Ejection Fraction (LVEF), 91% slowing of progression, p=0.041).
• Additional analyses in March 2026 from HOPE-3 demonstrated a statistically significant reduction in myocardial fibrosis (p=0.022) and a 3.3 percentage-point LVEF improvement in patients with baseline cardiomyopathy (p=0.017).
• The company's exosome platform, StealthX, is developing vaccine candidates for SARS-CoV-2, with a Phase 1 clinical study ongoing in collaboration with NIAID, with final results expected in Q2 2026.
• Capricor reported a net loss of approximately $105.0 million for the year ended December 31, 2025, compared to approximately $40.5 million in 2024.
• Cash, cash equivalents, and marketable securities totaled approximately $318.1 million as of December 31, 2025.
• The company raised approximately $237.0 million in net proceeds from common stock sales and $11.9 million from warrant and option exercises in 2025.
• Research and Development (R&D) expenses increased by approximately $34.5 million, or 69%, to $84.5 million in 2025, driven by the DMD program, exosome research, and facility expansion.
• General and Administrative (G&A) expenses increased by approximately $8.8 million, or 59%, to $23.7 million in 2025, due to increased headcount, professional services, and corporate overhead.
• Capricor has exclusive distribution agreements with Nippon Shinyaku for Deramiocel in the U.S. and Japan, with potential milestones up to $80.0 million upon U.S. marketing approval and up to $89.0 million for Japan.
• A binding term sheet with Nippon Shinyaku for European commercialization is under negotiation, with potential upfront payment of $20.0 million and up to $715.0 million in milestones.
• The California Institute for Regenerative Medicine (CIRM) Award was converted into a loan in February 2025, with a total liability of approximately $6.4 million as of December 31, 2025, including $3.0 million in accrued interest.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a moderately positive update. While the CRL was a setback, the positive Phase 3 data and accepted resubmission with a new PDUFA date provide a clear path forward for Deramiocel, and the strong cash position supports continued development.

Positives

• Deramiocel's Biologics License Application (BLA) for Duchenne muscular dystrophy (DMD) is under FDA Priority Review, with a new PDUFA target action date of August 22, 2026.
• Positive topline results from the Phase 3 HOPE-3 trial showed statistical significance in both the primary endpoint (PUL v2.0 Total Score, 54% slowing of progression, p=0.029) and the key secondary cardiac endpoint (Left Ventricular Ejection Fraction (LVEF), 91% slowing of progression, p=0.041).
• Additional analyses from HOPE-3 in March 2026 demonstrated a statistically significant reduction in myocardial fibrosis (p=0.022) and a 3.3 percentage-point improvement in LVEF compared to placebo in patients with baseline cardiomyopathy (p=0.017).
• Deramiocel maintained a favorable safety and tolerability profile consistent with prior clinical experience.
• The StealthX exosome vaccine candidate for SARS-CoV-2 is in an ongoing Phase 1 clinical study with NIAID, demonstrating a generally well-tolerated and favorable safety profile across all dose levels tested.
• The company maintains a strong financial position with approximately $318.1 million in cash, cash equivalents, and marketable securities as of December 31, 2025.
• Significant funding has been received through equity financings and collaboration payments, totaling approximately $600 million since inception.
• The FDA completed its Pre-License Inspection (PLI) of the San Diego manufacturing facility, and all Form 483 observations were addressed and accepted.
• Expansion of the San Diego headquarters by approximately 22,000 square feet is underway to support future manufacturing scale-up and anticipated commercial demand.
• Existing exclusive distribution agreements with Nippon Shinyaku for Deramiocel in the U.S. and Japan include substantial potential milestone payments ($80.0 million for U.S. marketing approval, up to $89.0 million for Japan).
• Negotiations for European commercialization with Nippon Shinyaku are ongoing, with potential for a $20.0 million upfront payment and up to $715.0 million in additional development and sales-based milestones.

Negatives

• The FDA issued a Complete Response Letter (CRL) in July 2025 for Deramiocel's BLA, stating the application did not meet the statutory requirement for substantial evidence of effectiveness and requested additional clinical data.
• The company reported a significant net loss of approximately $105.0 million for the year ended December 31, 2025, a substantial increase from $40.5 million in 2024.
• An accumulated deficit of approximately $304.9 million was reported as of December 31, 2025.
• No product revenue has been generated to date, and profitability is contingent on successful development, regulatory approval, and commercialization.
• Research and Development (R&D) expenses increased by 69% and General and Administrative (G&A) expenses increased by 59% in 2025, contributing to higher operating losses.
• Early analyses of the StealthX vaccine showed limited neutralizing antibody responses at evaluated dose levels, which may reflect prior vaccination or infection among trial participants.
• The last-to-expire patent licensed under the Rome License Agreement expired on January 4, 2026, potentially reducing intellectual property protection for certain aspects of CDC technology.
• The Cedars-Sinai Medical Center (CSMC) manufacturing facility, used for earlier clinical studies, is not cGMP-qualified for commercial manufacturing, and the lease is not planned to extend beyond mid-2026.
• The CIRM Award was converted into a loan, incurring approximately $3.0 million in accrued interest as of December 31, 2025, with potential for further accrual up to $7.7 million.
• Three legal proceedings (one putative securities class action, two derivative actions) and a Section 220 Shareholder Demand Letter were filed against the company in 2025, alleging violations of securities laws and breaches of fiduciary duties.

Risks

• Substantial additional funding may be required to complete the development and potential commercialization of product candidates in the United States and internationally.
• The company has incurred significant losses and may never achieve or sustain profitability.
• The occurrence of security breaches, improper access to or disclosure of data, and other cyber incidents could subject the company to liability or interrupt business operations.
• The company may not have adequate personnel and may not be able to attract or retain personnel necessary to develop and potentially commercialize product candidates.
• Success depends upon the viability of product candidates, which require regulatory approval prior to commercialization, and there is no certainty any of them will receive such approval.
• Delays in the commencement, enrollment or completion of clinical testing could result in increased costs and may delay or limit the ability to obtain regulatory approval for product candidates.
• The company may not be able to manufacture Deramiocel in sufficient quantities or at acceptable cost to meet market demand.
• Product candidates can fail to meet safety or efficacy endpoints at any time during the clinical development process, which would likely prevent them from becoming commercial products.
• The company may not be able to satisfy clinical or regulatory requirements necessary for the approval of product candidates in the U.S., Europe, Japan or other select territories.
• Failure to reach the milestones set forth in distribution agreements may prevent the company from receiving the financial benefits associated with those agreements.
• Exosome technologies may not demonstrate sufficient biological activity or scalability in development.
• Partners may not perform as expected, and therefore the company may not realize the anticipated benefits of those agreements.
• The successful commercialization of product candidates will depend in part on the extent to which governmental authorities and health insurers establish coverage, adequate reimbursement levels and pricing policies.
• The manufacturing of product candidates is dependent on complex supply chains, including the availability of donor hearts and other raw materials.
• The company may need to rely upon third-party manufacturers to expand manufacturing capabilities for later-stage clinical trials and potential commercialization.
• The company may not have sufficient manufacturing capacity or facilities required for any future scale-up of manufacturing.
• The company may not be able to successfully replicate or scale manufacturing processes or comply with current Good Manufacturing Practice (cGMP) regulations.
• The FDA may not ultimately determine that manufacturing processes are comparable or acceptable, or approve manufacturing facilities for commercial production.
• The company may face uncertainty and difficulty in obtaining and enforcing patents and other proprietary rights.
• The company may face potential challenges to the validity, enforceability, or scope of its intellectual property.
• The company may experience claims from third parties that it is infringing their patents or other intellectual property rights.
• The company may not be able to satisfy its obligations under its licensing agreements.
• The company depends on its relationships with its licensors, collaborators, and other third parties, and these relationships may not continue or may not be successful.
• The company will depend on the ability of Nippon Shinyaku to perform according to the terms of the U.S. Distribution and Japan Distribution Agreements and all applicable laws, and to successfully commercialize Deramiocel for the treatment of DMD.
• Products, if approved, will likely face significant competition.
• Any product candidates for which regulatory approval is received may not achieve broad market acceptance, which could limit the revenue generated from their sales.
• Products or product candidates may expose the company to potential product liability.
• The stock price is expected to continue to fluctuate significantly.
• The company has never paid dividends and does not anticipate paying dividends in the future.
• The company may issue shares of blank check preferred stock without stockholder approval in the future.
• Market and economic conditions may adversely affect the industry, business, and ability to obtain financing.
• The operational and other projections and forecasts that the company may make from time to time are subject to inherent risks, many of which are beyond its control.
• The certificate of incorporation and by-laws contain provisions that may discourage, delay or prevent a change in management team that stockholders may consider favorable.
• A significant number of shares of common stock are issuable pursuant to outstanding stock awards and warrants, and additional stock awards and shares of common stock are expected to be issued in the future, leading to dilution.
• The company's ability to utilize net operating loss and tax credit carryforwards in the future is subject to substantial limitations.
• The requirements of being a public company may strain resources and divert management's attention from operating the business.
• Failure to achieve and maintain effective internal controls in accordance with Section 404 of the Sarbanes-Oxley Act of 2002 could have a material adverse effect on the business and stock price.
• Short sellers may engage in market manipulating activities and seek to drive down the market price of common shares.
• The company may be at risk of securities class action litigation or litigation initiated by individual stockholders.

Future Outlook

Deramiocel's Biologics License Application (BLA) for Duchenne muscular dystrophy (DMD) has a new PDUFA target action date of August 22, 2026, for potential U.S. approval. The company intends to commercialize Deramiocel in the U.S. and seek strategic partners for international markets if approved. Regulatory engagement in Europe and Japan has been initiated to determine appropriate regulatory pathways for Deramiocel. Final results from the Phase 1 clinical study of the StealthX vaccine candidate for SARS-CoV-2 are expected in Q2 2026, with NIAID potentially considering a funded Phase 2 study. Expected R&D spending for the Deramiocel program in 2026 is approximately $100.0 million to $125.0 million, primarily for CMC expansion, product inventory buildout, clinical, regulatory, and pre-commercial expenses. R&D spending for the exosome program in 2026 is projected at approximately $7.0 million to $10.0 million. Negotiations with Nippon Shinyaku for European commercialization of Deramiocel are extended to April 1, 2026. The company believes its current cash, cash equivalents, and marketable securities are sufficient to fund operating capital requirements for at least the next twelve months from the issuance date of the financial statements.

Management Comments

• We believe therapies that address inflammatory and fibrotic processes contributing to muscle degeneration may provide potential benefit across a broad population of individuals with DMD.
• If approved, Deramiocel has the potential to become the first therapy designed to address both skeletal and cardiac muscle manifestations of Duchenne muscular dystrophy.
• Our current strategy is focused on advancing these programs through collaborations and partnerships that may provide additional development resources and capital to support potential clinical development.
• We believe this facility [San Diego manufacturing] is capable of supporting initial commercial supply of Deramiocel, subject to regulatory approval.
• We believe that our current cash, cash equivalents, and marketable securities are sufficient to fund our operating capital requirements for at least the next twelve months from the issuance date of these consolidated financial statements.

Industry Context

StockSavvy.ai notes that Capricor Therapeutics operates in the highly competitive biotechnology and pharmaceutical sectors, particularly in the rare disease space for Duchenne muscular dystrophy (DMD). The company's Deramiocel, a cell therapy, aims to address both skeletal and cardiac muscle manifestations, a distinct mechanism from mutation-targeted approaches like exon-skipping oligonucleotides and gene therapies. The exosome platform represents a novel therapeutic approach, facing challenges in a relatively unproven field where scalability and predictable biological activity have been historical hurdles for others. The ongoing development of a COVID-19 vaccine candidate places Capricor in a crowded market with established players and rapid technological change.

Comparison to Industry Standards

• Deramiocel's mechanism of action (immunomodulatory, anti-inflammatory, pro-angiogenic, anti-fibrotic) is distinct from mutation-targeted approaches in DMD, potentially offering a complementary therapeutic strategy.
• Competitors in the DMD space include Sarepta Therapeutics, Inc. with exon-skipping therapies (EXONDYS 51, AMONDYS 45, VYONDYS 53) and gene therapy (ELEVIDYS), and Nippon Shinyaku Co., Ltd. with VILTEPSO.
• The exosome platform is a novel therapeutic approach, with no products based on exosomes yet approved in the U.S., indicating it is an emerging field with significant development challenges compared to more established drug modalities.

Management Changes

Corporate Governance

Legal Proceedings

• A putative securities class action was filed on July 17, 2025, in the Southern District of California, naming Capricor Therapeutics, Inc. and its CEO, Linda Marbn, alleging violations of U.S. federal securities laws and seeking unspecified damages.
• A derivative action was filed on August 1, 2025, in the Southern District of California, naming the Directors of Capricor Therapeutics, Inc., alleging breaches of fiduciary duties and seeking unspecified damages.
• A second derivative action was filed on November 24, 2025, in the Southern District of California, naming the Directors of Capricor Therapeutics, Inc., alleging breaches of fiduciary duties and seeking unspecified damages.
• The company received a Section 220 Shareholder Demand Letter on October 2, 2025, to inspect certain books and records, related to alleged false and misleading statements and failure to disclose material adverse facts.
• No material accruals for loss contingencies were recorded as of December 31, 2025.

Related Party Transactions

• Consulting Agreement with Dr. Frank Litvack (Executive Chairman and Director) for $10,000 per month for consulting services.
• Commercialization and Distribution Agreements with Nippon Shinyaku (a related party holding more than 10% of outstanding capital stock) for U.S. and Japan distribution of Deramiocel.
• Binding Term Sheet with Nippon Shinyaku for European commercialization of Deramiocel.
• Private Placement with Nippon Shinyaku on September 16, 2024, where Nippon Shinyaku purchased 2,798,507 shares of common stock for approximately $15.0 million.

Stakeholder Impact

• Shareholders: Potential for significant returns if Deramiocel receives FDA approval and achieves commercial success, but also faces dilution from recent and future equity offerings, and risks from ongoing litigation and operating losses.
• Patients (DMD): Potential for a new therapeutic option (Deramiocel) that addresses both skeletal and cardiac muscle manifestations, offering hope for slowing disease progression.
• Employees: Increased headcount and expanded facilities indicate growth opportunities, but also potential for increased workload and pressure to meet development and commercialization milestones.
• Nippon Shinyaku: As a key distributor and significant shareholder, its success is tied to Deramiocel's approval and commercial performance, with substantial milestone payments at stake.
• Regulatory Authorities (FDA, EMA, PMDA): Ongoing engagement and scrutiny of clinical data and manufacturing processes, with the PDUFA date being a critical decision point.

Next Steps

• Await FDA decision on Deramiocel BLA by PDUFA target action date of August 22, 2026.
• Prepare for potential commercialization of Deramiocel in the U.S., including expanding manufacturing capabilities and commercial infrastructure.
• Continue regulatory engagement in Europe and Japan for Deramiocel.
• Final results from the Phase 1 clinical study of the StealthX vaccine candidate for SARS-CoV-2 are expected in Q2 2026.
• Prepare for a potential funded Phase 2 study for the StealthX vaccine if NIAID criteria are met.
• Continue negotiations with Nippon Shinyaku to finalize a definitive agreement for European commercialization by April 1, 2026.
• Evaluate potential additional therapeutic indications for Deramiocel beyond DMD (e.g., Becker muscular dystrophy).
• Advance the exosome platform for therapeutic development through internal research, strategic collaborations, and partnerships.
• Continue to enhance, refine, and optimize manufacturing processes and quality systems.
• Vacate the Cedars-Sinai Medical Center (CSMC) manufacturing facility by mid-2026.
• Finalize terms of the CIRM Award conversion into a loan.

Key Dates

Recommendation

Capricor Therapeutics presents a mixed but cautiously optimistic outlook. The positive Phase 3 HOPE-3 data for Deramiocel in DMD and the accepted BLA resubmission with a new PDUFA date are significant catalysts. However, the prior Complete Response Letter and the substantial net loss for 2025 highlight the inherent risks and high costs of clinical-stage biotech. While the strong cash position provides runway, the company has no approved products and faces intense competition and regulatory hurdles. The ongoing legal proceedings add a layer of uncertainty. A 'hold' recommendation is appropriate as investors await the critical FDA approval decision, balancing the significant upside potential with the considerable execution and market risks.

Keywords

Capricor Therapeutics, Duchenne Muscular Dystrophy, Deramiocel, FDA Approval, Cell Therapy, Exosomes, Biologics License Application, Clinical Trials, Rare Disease, Nippon Shinyaku, StealthX, PDUFA, HOPE-3, Corporate Governance, Capital Raise, Biotechnology, Orphan Drug, RMAT, Financial Results